SciSparc Ltd. (SPRC) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SciSparc Ltd., a pharmaceutical company specializing in central nervous system disorders, has received FDA approval to advance its proprietary SCI-110 drug into Phase IIb clinical trials for the treatment of Tourette Syndrome in adult patients. The company, which had previously demonstrated promising results in Phase IIa trials, will conduct the new trials across three global centers of excellence. SciSparc’s CEO expressed confidence in the drug’s potential to offer a novel treatment for Tourette’s patients.
For further insights into SPRC stock, check out TipRanks’ Stock Analysis page.